Alertă pentru pacienții care folosesc GLP-1 să slăbească: sute de procese invocă un risc rar de pierdere a vederii

Patients using GLP-1 receptor agonists have filed lawsuits claiming these medications may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to sudden vision loss. Companies like Novo Nordisk and Eli Lilly deny these allegations. NAION occurs when blood supply to the optic nerve is suddenly reduced, often affecting one eye. Studies have shown a modestly increased risk of NAION associated with semaglutide, a key ingredient in some GLP-1 medications, but the absolute risk remains low. Regulatory agencies are cautiously reviewing the evidence, with the FDA and EMA acknowledging a potential link. Experts advise patients not to stop their GLP-1 treatments without consulting a doctor, weighing the benefits against potential risks.